参考文献/References:
[1].Frostegard J. Immunity, atherosclerosis and cardiovascular disease [J]. BMC Med, 2013,11 (117):1-13.
[2].Liu A, Frostegard J. PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque [J]. J Intern Med, 2018,284(2):193-210.
[3].Sun H, Krauss RM, Chang JT,et al. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction[J].J Lipid Res, 2018, 59(2): 207-223.
[4].Sorci-Thomas MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis [J]. Circ Res, 2016,118(4):679-691.
[5].Giunzioni I, Tavori H, Covarrubias R,et al. Local effects of human PCSK9 on the atherosclerotic lesion [J]. J Pathol, 2016,238(1):52-62.
[6].Onat D, Brillon D, Colombo PC,et al. Human vascular endothelial cells: a model system for studying vascular inflammation in diabetes and atherosclerosis[J]. Curr Diab Rep, 2011,11(3):193-202.
[7].Ferri N, Tibolla G, Pirillo A,et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels [J]. Atherosclerosis, 2012,220(2):381-386.
[8].Urban D, Poss J, Bohm M,et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis [J]. J Am Coll Cardiol, 2013,62(16):1401-1408.
[9].Hirose K, Iwabuchi K, Shimada K,et al. Different responses to oxidized low-density lipoproteins in human polarized macrophages [J]. Lipids Health Dis,2011,10(1):1-18.
[10].Bernelot Moens SJ, Neele AE, Kroon J,et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia [J]. Eur Heart J,2017,38(20):1584-1593.
[11].Ruscica M, Ricci C, Macchi C,et al. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line [J]. J Biol Chem,2016,291(7):3508-3519.
[12].Al-Sharea A, Lee MK, Moore XL,et al. Native LDL promotes differentiation of human monocytes to macrophages with an inflammatory phenotype [J]. Thromb Haemost, 2016,115(4):762-772.
[13].Tang ZH, Peng J, Ren Z,et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway[J]. Atherosclerosis, 2017,262(2):113-122.
[14].Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis [J]. Cell, 2011,145(3):341-355.
[15].Li J, Liang X, Wang Y,et al. Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis [J]. Mol Med Rep, 2017,16(2):1817-1825.
[16].Wu CY, Tang ZH, Jiang L,et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway [J]. Mol Cell Biochem,2012,359(1-2):347-358.
[17].Tellides G, Pober JS. Inflammatory and immune responses in the arterial media [J]. Circ Res, 2015,116(2):312-322.
[18].Ding Z, Liu S, Wang X,et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis[J]. Cardiovasc Res, 2014,103(4):619-628.
[19].Ding Z, Liu S, Wang X,et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues [J]. Cardiovasc Res, 2015,107(4):556-567.
[20].Ding Z, Liu S, Wang X,et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta [J]. Antioxid Redox Signal,2015,22(9):760-771.
[21].Grune J, Meyborg H, Bezhaeva T,et al. PCSK9 regulates the chemokine receptor CCR2 on monocytes [J]. Biochem Biophys Res Commun, 2017,485(2):312-318.
[22].Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans [J]. Arterioscler Thromb Vasc Biol, 2015,35(4):763-770.
[23].Ketelhuth DF, Hansson GK. Adaptive Response of T and B Cells in Atherosclerosis [J]. Circ Res, 2016,118(4):668-678.
[24].Cheng HY, Gaddis DE, Wu R,et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis [J]. J Clin Invest, 2016,126(9):3236-3246.
[25].Liu A, Ming JY, Fiskesund R,et al. Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins [J]. Arterioscler Thromb Vasc Biol,2015,35(1):197-205.
[26].Frostegard J, Zhang Y, Sun J,et al. Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect [J]. J Am Heart Assoc, 2016,5(9) pii: e003976. .
[27].Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis [J]. Thromb Haemost, 2011,106(5):787-795.
[28].Lim H, Kim YU, Sun H,et al. Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo [J]. Immunity, 2014,40(1):153-165.
[29].Gistera A, Robertson AK, Andersson J,et al. Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway [J]. Sci Transl Med, 2013,5(196):196ra100.
[30].Liu Z, Lu F, Pan H,et al. Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication [J]. Atherosclerosis ,2012,221(1):232-241.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(7):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(7):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(7):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(7):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(7):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(7):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(7):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[11]肖明瑛 苏冠华.PCSK9抑制剂多效性研究进展[J].心血管病学进展,2022,(2):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
XIAO MingyingSU Guanhua.Pleiotropic Effects of PCSK9 Inhibitors[J].Advances in Cardiovascular Diseases,2022,(7):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
[12]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(7):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]